
Beyond Sparse Clinical Knowledge
Jungla develops a next-generation molecular function software platform that continuously integrates and enhances clinical knowledge with auditable functional and computational evidence across genetic and genomic tests. The platform enables robust, scalable clinical guidance for molecular diagnostic, screening, and therapeutic intervention tests — placing data from each patient at the service of the next. Jungla was acquired by Invitae in 2019 to advance genetic variant interpretation.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account